CD274 and lung cancer: The pooled rate of response after RECIST-defined PD was higher for melanoma (7.2%) than lung cancer (4.0%), which may reflect the higher conventional RECIST-defined response rate observed for anti-PD-1/PD-L1 treatment as single agent in melanoma patients as compared as patients with lung cancer.